中國心連心化肥(01866.HK)年度純利增272.24%至12.94億元 末期息19分
格隆匯3月26日丨中國心連心化肥(01866.HK)公佈年度業績,截至2021年12月31日止12個月,公司收入為人民幣168.15億元,同比增長60.99%;毛利為人民幣43.89億元,同比增長98.18%;母公司擁有人應占溢利為人民幣12.94億元,同比增長272.24%;每股盈利為人民幣110.46分,擬派末期股息每股普通股人民幣19分。
隨着疫情再次爆發,加上全球供應鏈中斷以及能源及食品價格飆升,國內化肥及石油化工相關產品於2021年的需求及價格上漲。
江西九江第三生產基地於2021年2月順利投產,集團於河南新鄉的第二及第三廠固定牀改造升級項目亦於2021年第四季度竣工投產,集團的生產產能及效率進入新的里程碑,實現創紀錄的收入及盈利能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.